Indian scientists introduce a new low-cost vaccine against a virus which kills thousands of children across the world each year. Rotavac, the new vaccine, kills Rotavirus, which causes diarrhea spreads through contaminated water and hands and it rampant in Asia and Africa.
The clinical trials in India prove the vaccine can save the lives of thousands of children globally each year. The report from the manufacturer says, the vaccine can purchase at the cost of 54 rupees ($1; £0.65).
GlaxoSmithKline and Merck, the international companies produce the same vaccine and available in the market at the cost of $18.27 for each dose.
K Vijay Raghavan, an official from the Department of Biotechnology India said it will be an absolute solution against rotavirus infections. It is severe and lethal cause of childhood diarrhea kills 100,000 small children in India annually. He added that, if the vaccine licensed, it could save the lives of thousands of children in India each year.
Bharat Biotech, Hyderabad-based, manufacturer said, once the clearance completed, the company can produces tens of millions of doses and everything expected to be completed within eight months.
The studies conducted by Bharat Biotech International, Ltd reveal that Rotavirus’ are the serious reason for the contagious diarrhea illness in infants and young children in both developed and undeveloped countries.
K. Vijaraghavan, secretary of India’s Department of Biotechnology says, “It will be a world class vaccine for Indian children.”
The scientist reports that, the virus blamed for the cause of the hospitalization of 884,000 children in India each year, and the approximate cost is $72 million for treatment.
Each vaccination includes three doses, which will be a breakthrough in the Rotavac vaccine application.
Each year Rotavirus kills around 435,000 children under 5 years old and, hospitalizes two million children across the world, especially in developing countries. The condition of the children between 2 months and 6 years old are too vulnerable.
In 2006, two oral Rotavirus vaccines licensed and available in America and Europe, which leads to the eradication of Rotavirus-induced diarrhea in a great extent. In 2009, the success application of the vaccine leads WHO to exhort all nations to include the vaccine to all immunizations programs.
The National Institute of Allergy and Infectious Diseases ((NIAID), part of the U.S. National Institutes of Health was a partner to develop and trial the vaccine. In fact, this is an output of Indo US collaboration vaccine action program.
As a joint venture, the clinical trials were conducted in Cincinnati Children’s Hospital, NIAID funded vaccine and treatment evaluation unit.
By: Bindu Jacob